Sepsis accounts for high mortality rates in critical care units. Prompt and accurate identification of causative pathogens and initiation of appropriate antimicrobial therapy is critical for the appropriate management of patients in order to optimise clinical outcomes. The BioFire FilmArray blood culture identification (BCID) panel is a US Food and Drug Administration (FDA) approved rapid, multiplex polymerase chain reaction (PCR) assay that is able to identify a variety of bacteria, fungi and antimicrobial resistance determinants directly from positive blood cultures. The aim of this study was to evaluate the diagnostic performance of the BioFire FilmArray BCID panel against the gold standard of blood cultures. Seventy-eight positive blood cultures obtained from critically ill patients suspected of having sepsis were included in the study. Each bottle was processed with the BioFire FilmArray BCID panel as well as conventional culture methods. Diagnostic accuracy of the BioFire FilmArray BCID panel was determined. The assay demonstrated a high sensitivity and specificity for pathogen identification of 96.5% (95% CI, 91.3–99.0) and 99.7% (95% CI, 99.3–99.9), respectively. The findings of this study support the role of the BioFire FilmArray BCID panel in the management of critically ill patients with sepsis.

脓毒症导致重症监护病房的高死亡率。及时准确地识别致病病原体并启动适当的抗菌治疗对于适当管理患者以优化临床结果至关重要。BioFire FilmArray 血培养鉴定 (BCID) 面板是美国食品和药物管理局 (FDA) 批准的快速多重聚合酶链反应 (PCR) 检测方法，能够直接从阳性血液中鉴定各种细菌、真菌和抗菌素耐药性决定因素文化。本研究的目的是根据血培养金标准评估 BioFire FilmArray BCID 面板的诊断性能。该研究包括从怀疑患有败血症的危重患者中获得的 78 例阳性血培养。每个瓶子都使用 BioFire FilmArray BCID 面板以及传统的培养方法进行处理。确定了 BioFire FilmArray BCID 面板的诊断准确性。该检测方法对病原体鉴定的敏感性和特异性分别为 96.5%（95% CI，91.3-99.0）和 99.7%（95% CI，99.3-99.9）。这项研究的结果支持 BioFire FilmArray BCID 小组在脓毒症重症患者管理中的作用。